HIV/AIDS Treatment for Millions

See allHide authors and affiliations

Science  13 Apr 2001:
Vol. 292, Issue 5515, pp. 221-223
DOI: 10.1126/science.1057504

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Pharmaceutical companies have at last announced sharp price reductions for antiretroviral (ARV) medication in Africa. Prices offered by generic manufacturers are even lower. If competition among generic drug producers and patent holders can be maintained or intensified, further drops in ARV prices are likely. Millions can now afford the drugs. Many more millions are uninsured and cannot afford to pay. Nor can governments of poor countries afford to subsidize the drugs. Large donation programs must therefore be financed by public and private donations from developed countries. Fast expansion of ARV treatment requires quick complementary actions by associations of people living with HIV/AIDS, medical associations, and private and public donors, and facilitating actions by poor governments, and international organizations.